PEG-MGF vs Cartalax
Side-by-side comparison of key properties, dosing, and research.
- Summary
- PEG-MGF (Pegylated Mechano Growth Factor) is a modified form of MGF (Mechano Growth Factor) where polyethylene glycol (PEG) chains have been attached to extend its half-life from minutes to days. Native MGF is released locally in muscle in response to mechanical stress and quickly degrades. PEGylation allows systemic administration with sustained circulation, enabling whole-body muscle repair and anabolic signaling rather than the purely local effect of native MGF.
- Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
- Half-Life
- ~3 days (due to PEGylation)
- Short (minutes); gene-regulatory effects are sustained
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 200–400 mcg
- 10 mg per day
- Frequency
- 2–3x per week
- Daily for 10–30 days
- Key Benefits
- Extended half-life (~3 days) vs native MGF (minutes)
- Systemic muscle satellite cell activation via subcutaneous injection
- Promotes muscle fiber repair and hypertrophy throughout the body
- Enhanced recovery from intense training or muscle injury
- Synergistic with IGF-1 LR3 and growth hormone peptides
- Useful in sarcopenia, post-injury recovery, and athletic performance
- Single injection provides multi-day anabolic signaling
- Supports cartilage matrix synthesis and maintenance
- May slow progression of osteoarthritic cartilage degradation
- Reduces chondrocyte apoptosis
- Promotes joint longevity in aging and high-impact sports
- Anti-aging effects on connective tissue
- Complementary to BPC-157 and TB-500 in joint recovery protocols
- Well tolerated in available human and animal research
- Side Effects
- Water retention and localized swelling
- Potential hypoglycemia at high doses
- Theoretical cancer growth risk (growth factor)
- Injection site reactions
- +1 more
- Generally well tolerated
- Mild injection site reactions
- No significant adverse events reported at standard doses
- Stacks With
- —
- —